Which of the following factors supports the initiation of antilipemic medications?

The initiation of antilipemic medications is primarily supported by elevated levels of low and non-high-density lipoprotein cholesterol. High levels of low-density lipoprotein (LDL) are a significant risk factor for cardiovascular diseases, as LDL cholesterol contributes to the development of atherosclerosis and other heart-related issues. Antilipemic medications are designed to lower these levels, thereby reducing the risk of heart attacks and strokes.

When LDL levels are elevated, it indicates a need for intervention to manage and mitigate potential cardiovascular risks. Non-high-density lipoprotein (non-HDL) cholesterol is also an important target for therapy since it includes all atherogenic lipoproteins. Thus, high levels of both LDL and non-HDL cholesterol directly support the decision to initiate treatment with antilipemic agents to promote better lipid management and improve overall cardiovascular health.